BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 2967850)

  • 1. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
    Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
    J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-secreting pituitary tumor: biosynthetic characterization and clinical studies.
    Klibanski A; Deutsch PJ; Jameson JL; Ridgway EC; Crowley WF; Hsu DW; Habener JF; Black PM
    J Clin Endocrinol Metab; 1987 Mar; 64(3):536-42. PubMed ID: 3102541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.
    Chanson P; Lahlou N; Warnet A; Roger M; Sassolas G; Lubetzi J; Schaison G; Bouchard P
    J Endocrinol Invest; 1994 Feb; 17(2):91-8. PubMed ID: 8006338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.
    Lahlou N; Roger M; Chaussain JL; Feinstein MC; Sultan C; Toublanc JE; Schally AV; Scholler R
    J Clin Endocrinol Metab; 1987 Nov; 65(5):946-53. PubMed ID: 2959680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist.
    McGrath GA; Goncalves RJ; Udupa JK; Grossman RI; Pavlou SN; Molitch ME; Rivier J; Vale WW; Snyder PJ
    J Clin Endocrinol Metab; 1993 May; 76(5):1363-8. PubMed ID: 8496331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist.
    Daneshdoost L; Pavlou SN; Molitch ME; Gennarelli TA; Savino PJ; Sergott RC; Bosley TM; River JE; Vale WW; Snyder PJ
    J Clin Endocrinol Metab; 1990 Jul; 71(1):92-7. PubMed ID: 2115048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function correlations of human pituitary gonadotroph adenomas in vitro.
    Asa SL; Gerrie BM; Kovacs K; Horvath E; Singer W; Killinger DW; Smyth HS
    Lab Invest; 1988 Apr; 58(4):403-10. PubMed ID: 2451766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.
    Kwekkeboom DJ; de Jong FH; Lamberts SW
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1128-35. PubMed ID: 2542356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
    Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
    J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors.
    Popovic V; Damjanovic S
    Thyroid; 1998 Oct; 8(10):935-9. PubMed ID: 9827662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of a gonadotrophin-releasing hormone agonist ([D-Ser(But)6]GnRH(1-9)nonapeptide-ethylamide) on gonadotrophin secretion from human pituitary gonadotroph cell adenomas in vitro.
    Daniels M; Newland P; Dunn J; Kendall-Taylor P; White MC
    J Endocrinol; 1988 Sep; 118(3):491-6. PubMed ID: 2460576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro.
    Lamberts SW; Verleun T; Oosterom R; Hofland L; van Ginkel LA; Loeber JG; van Vroonhoven CC; Stefanko SZ; de Jong FH
    J Clin Endocrinol Metab; 1987 Mar; 64(3):524-30. PubMed ID: 3102540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotroph cell adenomas of the pituitary.
    Snyder PJ
    Endocr Rev; 1985; 6(4):552-63. PubMed ID: 2416559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L; Albertsson-Wikland K; Phillips DJ
    J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.